DULUTH, Ga. (Nov. 11, 2021) — Boehringer Ingelheim Animal Health announces two new hires in the U.S. Swine and Poultry divisions.
Sharon Holt, Director of Marketing, U.S. Swine and Poultry
Sharon Holt has been appointed to the role of Director of Marketing for U.S. Swine and Poultry. Holt has more than 19 years of leadership experience and an intrinsic knowledge of the Boehringer Ingelheim Animal Health business across manufacturing, supply chain and commercial functions.
In this new role, Holt will lead the marketing teams for both the Swine and Poultry divisions and work closely with U.S. and global leadership.
Holt started her career at Boehringer Ingelheim in 2002 as a laboratory technician at the Athens, Georgia, vaccine manufacturing and research site, and since then has held roles within the Poultry and Pet divisions and U.S. Commercial Operations. In her most recent role, Holt was responsible for leading the Commercial Supply Chain group’s Customer Care team, which is focused on creating positive experiences for Boehringer Ingelheim customers.
Dr. Rick Phillips, Director of Poultry Professional Services Veterinarians
Dr. Rick Phillips has joined Boehringer Ingelheim Animal Health as the Director of U.S. Poultry Professional Services
veterinarians. In this role, Dr. Phillips is responsible for leading the U.S. poultry professional services veterinary team, and will work in collaboration with the poultry leadership team to advance the mission of bringing innovative health solutions to poultry customers.
Dr. Phillips brings more than 26 years of poultry industry experience with companies such as Perdue Farms, Foster Farms, Merck Animal Health and Anitox, Inc. He has experience in both veterinary services and business, including oversight of technical support, strategic planning and team development.
Dr. Phillips holds a Doctor of Veterinary Medicine degree from Louisiana State University, Baton Rouge, a Master of Science degree from the University of Maine, Orono, and a Master of Avian Medicine from the University of Georgia.
Dr. Phillips will be a primary resource on poultry health for the industry on behalf of Boehringer Ingelheim.
“Both Sharon and Rick bring a tremendous level of experience and knowledge to their roles at Boehringer Ingelheim, and their respective teams are looking forward to utilizing their talent to better our offerings and the industry as a whole,” said Lara Sheeley, Executive Director of the U.S. Swine and Poultry divisions.
To learn more about Boehringer Ingelheim Animal Health, visit www.boehringer-ingelheim.us.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier, too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals, and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second-largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9 percen of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
©2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved.
For more information, please contact:
VP | Public Relations, broadhead
Head of External Communications & Content Strategy, Boehringer Ingelheim Animal Health